A retrospective cohort study of dalbavancin compared to standard-of-care (SOC) or vancomycin and daptomycin in invasive infections due to suspected or confirmed Gram-positive organisms
Latest Information Update: 29 Jul 2021
Price :
$35 *
At a glance
- Drugs Dalbavancin (Primary) ; Daptomycin; Vancomycin
- Indications Bacterial endocarditis; Gram-positive infections
- Focus Therapeutic Use
- 29 Jul 2021 New trial record